Call us on 0800 0195 322

Journal of Drugs in Dermatology: Clinical Study on Emepelle

Journal of Drugs in Dermatology: Clinical Study on Emepelle

Emepelle® is a breakthrough innovation for skin affected by menopause: It is the first and only cosmeceutical to feature MEP Technology, clinically proven to effectively and safely target the root cause of accelerated collagen loss and skin ageing due to the decline in oestrogen levels.

Esteemed US Dermatologist, Joel L. Cohen, led a clinical study which evaluated the efficacy and safety of using Emepelle to treat skin affected by menopause: Evaluation of Efficacy of a Skin Care Regimen Containing Methyl Estradiolpropanoate (MEP) for Treating Estrogen Deficient Skin

The research investigation, which has recently been published the Journal of Drugs in Dermatology, was a 20- week open label study on fourteen female subjects aged 53-68 years. Participants used Empelle Serum and Night Cream daily. Outcomes were assessed at week 8, week 12, and week 20 by clinical as well as subject graded improvement.

Key findings from the study included:

  • 100% of study participants showed aesthetic improvements per investigator-assessed Global Aesthetic Improvement Scale (GAIS) at week 14
  • 93% saw two grades or more improvement in the 0-4 Facial Hydration Scale at week 20
  • 93% of study participants responded that the combination of Emepelle Serum and Night Cream regimen helped improve wrinkles, texture, and color at week 20
  • In the Quality of Life questionnaire, 86% responded that Emepelle helped alleviate some or all of the skin issues they developed since entering menopause

You can read the clinical study here.

Emepelle was launched in the UK in March 2019. Leading Dermatologists and skin professionals are enthused about this new category of skincare that can address a previously unmet need in treating menopausal clients.

Harley Street Consultant Dermatologist, Dr Emma Wedgeworth tells us:

“Emepelle is a new category of skincare. It contains an active molecule, called MEP (methyl estradiolproponate) which is a non-hormonal oestrogen receptor agonist. MEP Technology is fascinating because it’s a way of directly targeting the skin cells, helping to boost the effects of an oestrogen like molecule, which is not actually a hormone. I’m very excited about the use of Emepelle and I think it’s really going to be an area that totally takes off because it’s really helping to target in a very intelligent way, the sorts of changes we see in menopausal skin.”

What next?

To find out more about becoming an Emepelle stockist, please complete the short form below. Alternatively, you can contact us on 0800 0195 322, or visit for further information.